Back to Results
First PageMeta Content
Immunology / Monoclonal antibodies / Autoimmune diseases / Gastroenterology / Infliximab / Adalimumab / Etanercept / TNF inhibitor / Disease-modifying antirheumatic drug / Medicine / Pharmacology / Immunosuppressants


sPeCiAl ArTiCle Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn’s disease Daniel C Sadowski MD1, Charles N Bernstein MD2, Alai
Add to Reading List

Document Date: 2011-05-26 17:34:53

Open Document

File Size: 645,37 KB

Share Result on Facebook

City

Edmonton / Winnipeg / Montreal / New York / Toronto / /

Company

SONIC / Pulsus Group Inc. / MEDLINE / Steering Group / /

Country

United States / Canada / /

/

Facility

Zeidler Ledcor Centre / Health Research Institute of Nutrition / Alexandra Hospital / stable Crohn’s / University of Alberta / Royal College of Physicians / /

/

IndustryTerm

pharmaceutical industry / search term / treatment of active Crohn’s disease / treatment algorithms / imaging / treatment of Crohn’s disease / lengthy trial-and-error treatment algorithm / Treatment for severe Crohn’s disease / /

MedicalCondition

transverse myelitis / inflammatory bowel disease / T cell lymphoma / tumour necrosis / chest pain / neurological disorders / rectovaginal fistulas / severe Crohn’s disease / intestinal inflammation / bronchitis / rheumatoid arthritis / cellulitis / luminal Crohn’s disease / demyelinating disorders / active fistulizing Crohn’s disease / colitis / intra-abdominal abscess / serum sickness / lymphadenopathy / multiple sclerosis / completely close Crohn’s disease / hypersensitivity / urinary tract infections / sinusitis / demyelinating diseases / Induction Regimens For fistulizing Crohn’s disease / moderate-to-severe disease activity / infections / sepsis / hypotension / congestive heart failure / pneumonia / laryngospasm / opportunistic infections / bacterial infections / disease / arthralgia / dyspnea / active Crohn’s disease / optic neuritis / moderate-to-severe Crohn’s disease / moderately-to-severely active Crohn’s disease / Crohn’s disease / histoplasmosis / pediatric Crohn’s disease / For fistulizing Crohn’s disease / erythema / itching / fever / abscesses / ulcerative colitis / active disease / abdominal and rectovaginal fistulas / opportunistic infection / Heart Failure / urticaria / angioedema / bacterial infection / pediatric inflammatory bowel disease / infection / irritation / moderate-to-severe disease / adult Crohn’s disease / irritable bowel syndrome / tumour necrosis factor / rash / pharyngitis / abscess / tuberculosis / /

MedicalTreatment

premedication / antibiotics / retreatment / Biologic therapy / concomitant therapy / induction of remission / concomitant immunosuppressive therapy / immunosuppression / drainage / immunosuppressive therapy / antibody therapy / antibiotic therapy / immunosuppression therapy / /

NaturalFeature

Statements Fall / /

Organization

1Royal Alexandra Hospital / Executive Committee / Zeidler Ledcor Centre / University of Alberta / Canadian Association of Gastroenterology Clinical Practice Guidelines / sPeCiAl ArTiCle Canadian Association of Gastroenterology Clinical Practice Guidelines / Division of Gastroenterology / 3McGill University / Montreal / Royal College of Physicians and Surgeons of Canada / Health Research Institute of Nutrition / Metabolism and Diabetes / l’Association / Canadian Association of Gastroenterology / /

Person

Charles N Bernstein / Anne Griffiths / Daniel C Sadowski / Richard N Fedorak / Alain Bitton / Ken Croitoru / /

/

Position

neurologist / advocate / nonvoting chair / surgeon / /

Product

acetaminophen / DS / mercaptopurine / B 52 / prednisone / azathioprine / TNF / hydrocortisone / /

ProvinceOrState

Alberta / Quebec / Manitoba / Ontario / /

Technology

alpha / Antibodies / pharmacokinetics / diagnostic imaging / lengthy trial-and-error treatment algorithm / treatment algorithms / conventional treatment algorithms / /

URL

www.cag-acg.org / /

SocialTag